Becton Dickinson & Co.

BDX ·Healthcare, Medical Devices, United States

Becton, Dickinson and Company (BDX)

Overview

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that manufactures and sells medical supplies, devices, and diagnostic/laboratory equipment used by hospitals, clinicians, and life-science researchers. It is headquartered in Franklin Lakes, New Jersey, and operates in the Health Care sector under the medical devices industry. For fiscal year 2025 (ended September 30, 2025), BD reported total revenue of about $21.8 billion and net income of roughly $1.68 billion. In February 2026, BD completed a major transaction combining its Biosciences and Diagnostic Solutions business with Waters Corporation, a move management describes as transforming BD into a "focused, pure-play MedTech company" concentrated on medical devices and interventional products rather than lab instrumentation and diagnostics.

What They Do & How They Make Money

BD earns money primarily by selling consumable medical devices — needles, syringes, IV catheters, infusion sets, and specimen-collection products — that hospitals, clinics, and labs use in enormous volumes every day, plus the durable equipment (infusion pumps, medication-management systems, surgical devices) that goes alongside them. Much of its revenue follows a "razor and razorblade" pattern: it places capital equipment (pumps, dispensing cabinets, catheter systems) with health systems and then earns recurring revenue from the disposable supplies and service contracts that equipment requires, creating sticky, repeat-purchase relationships. Its Interventional business generates revenue from device sales tied to specific surgical and procedural specialties, such as vascular access, urology, and surgical wound/hernia repair, often priced at a premium for differentiated or minimally invasive technology. Historically, BD also earned meaningful revenue from lab instruments, reagents, and diagnostic testing platforms through its Life Sciences segment, but that revenue stream now belongs to the newly combined Waters/BD Biosciences entity following the February 2026 separation, leaving BD's ongoing revenue concentrated in medication delivery, specimen management, and interventional devices sold globally, with the U.S. as its largest market.

Business Segments

Historically, BD reported three segments — BD Medical, BD Life Sciences, and BD Interventional — which for fiscal 2025 generated approximately $11.46 billion, $5.17 billion, and $5.22 billion in revenue, respectively. Following the February 2026 completion of the combination of the Biosciences and Diagnostic Solutions business (largely the former Life Sciences segment, including flow cytometry, diagnostics, and specimen management platforms) with Waters Corporation, BD's ongoing structure is now built around two core areas:

BD Medical — the largest segment, covering medication delivery and management (needles, syringes, IV catheters, prefillable devices, infusion/medication-management systems, and pharmaceutical systems) used broadly across hospitals and alternate care sites; this is BD's highest-volume, most recurring-revenue business.
BD Interventional — device-based procedural solutions across surgery (hernia and soft-tissue repair), peripheral intervention (vascular access and treatment), and urology/critical care, generally carrying higher margins tied to clinical differentiation.

The former Biosciences and Diagnostic Solutions/Life Sciences business (flow cytometry research tools, microbiology and molecular diagnostics, specimen management) is no longer part of BD's continuing operations as of the Waters combination.

Competitors

BD's competitive landscape differs by business line:

Medication delivery / needles & syringes / infusion: Baxter International (BAX), ICU Medical, B. Braun, Terumo, Smiths Medical.
Interventional (vascular access, urology, surgery): Boston Scientific, Medtronic, Teleflex, C.R. Bard (historically acquired by BD itself), Cook Medical.
Former Biosciences/diagnostics business (now combined with Waters): competes going forward against Thermo Fisher Scientific, Danaher (Beckman Coulter, Cepheid), Agilent, and Roche Diagnostics.

Competitive Position

BD's core strength is its position as one of the largest suppliers of everyday medical consumables — needles, syringes, and IV/vascular access devices — where its brand, manufacturing scale, and long-standing hospital relationships create durable, high-volume, recurring revenue that is relatively insulated from economic cycles (patients still need injections and IV access regardless of the economy). Its installed base of infusion pumps and medication-management systems locks in recurring consumables revenue and creates switching costs for hospital systems, since replacing pump platforms requires significant retraining and capital investment. The February 2026 separation of the Biosciences and Diagnostic Solutions business into a combined entity with Waters Corporation was designed to sharpen BD's strategic focus, simplify its portfolio around medication delivery and interventional devices — areas management believes benefit most from trends like smarter connected devices, AI-enabled care, and the shift of care to lower-cost settings — and let both resulting companies pursue capital allocation and R&D priorities suited to their distinct end markets (hospital device consumables versus lab instrumentation/diagnostics).

Key risks include pricing pressure from hospital group purchasing organizations and increasing generic/commodity competition in lower-differentiation product categories (basic needles and syringes); execution risk in fully realizing the benefits of the Waters transaction and operating as a narrower, more concentrated company; regulatory and quality risk typical of a large medical device manufacturer (FDA scrutiny, product recalls — BD has faced high-profile device-safety and litigation issues in the past, including with certain hernia mesh and alaris pump products); and reimbursement/healthcare-policy risk, since hospital capital budgets and procedure volumes are sensitive to payer policy and macroeconomic conditions. Currency exposure is also meaningful given BD's substantial international revenue base.